Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir potassium
Drug ID BADD_D01906
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status approved
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D07133
MeSH ID D000068898
PubChem ID 23668479
TTD Drug ID D0I1FQ
NDC Product Code 62331-055; 67317-0001; 67651-0275; 70600-028; 50473-0001; 67317-0031; 65977-0129; 67651-0276; 65015-841; 67651-0274
UNII 43Y000U234
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H20FKN6O5
CAS Registry Number 871038-72-1
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.001--Not Available
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.004--
Renal cyst20.01.04.001; 16.27.01.001--Not Available
Renal failure20.01.03.005--Not Available
Renal tubular necrosis20.01.07.003--Not Available
Rhabdomyolysis15.05.05.002--
Sinus bradycardia02.03.03.009--
Skin disorder23.03.03.007--Not Available
Skin lesion23.03.03.010--Not Available
Skin papilloma23.10.01.002; 16.26.01.002; 11.05.07.001--
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Squamous cell carcinoma16.16.01.002--Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.004--
Tendonitis15.07.01.003; 12.01.07.007--Not Available
Tension headache19.24.01.009; 17.14.01.004--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular extrasystoles02.03.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages